FE 999301

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Bladder CancerSeptic ShockInfertilityPrader-Willi SyndromePortal HypertensionPolyuria

378 competitors in Bladder Cancer

#DrugCompanyPhaseTrials

1

Gemzar

Johnson & Johnson

Phase 3

572

Keytruda

Merck & Co.

Phase 3

313

Taxol

Teva

Phase 3

154

Gemzar

GGynecologic Oncology Group

Phase 3

245

Velban

Eli Lilly

Phase 3

86

Iressa

AstraZeneca

Phase 3

27

Ellence

Merck & Co.

Phase 3

18

Cipro

Bayer

Phase 3

19

Mitomycin C

GGynecologic Oncology Group

Phase 3

1610

Bacillus Calmette-Guérin

Bristol-Myers Squibb

Phase 3

4Show 29 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Controlled Ovarian Stimulation2 trials

A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation.

Completed·Ferring·Phase 2·NCT03564509·620 enrolled

An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta at Different Time Intervals During Controlled Ovarian Stimulation.

Terminated·Ferring·Phase 1·NCT06511791·106 enrolled

Treatment2 trials

A Phase III Study of FE 999913 in Japanese Female Patients Undergoing Fertility Treatment

Completed·Ferring·Phase 3·NCT01710514·108 enrolled

A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI Treatment

Completed·Ferring·Phase 2·NCT01426386·265 enrolled

Septic Shock2 trials

Effects of the V1a Agonist FE 202158 in Patients With Septic Shock

Completed·Ferring·Phase 2·NCT01000649·53 enrolled

Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock

Completed·Ferring·Phase 2·NCT01612676·31 enrolled

Immunogenicity1 trial

Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Japanese Persons

Completed·Ferring·Phase 1·NCT06515834·24 enrolled

GnRH Antagonist1 trial

Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)

Completed·Ferring·Phase 3·NCT03809429·437 enrolled

9 more indications

Portal Hypertension1 trial

A Study to Investigate the Safety and Effect of the Study Drug (FE 204205) in Patients With Cirrhotic Portal Hypertension

Terminated·Ferring·Phase 1·NCT02929407·4 enrolled

Polyuria1 trial

A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults

Completed·Ferring·Phase 2·NCT03201419·302 enrolled

Prader-Willi syndrome1 trial

Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome

Completed·Ferring·Phase 2·NCT01968187·38 enrolled

Intracytoplasmic Sperm Injection1 trial

A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment

Completed·Ferring·Phase 2·NCT02309671·159 enrolled

Ovarian Stimulation1 trial

Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation

Withdrawn·Ferring·Phase 2·NCT05571111

Infertility1 trial

A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM)

Terminated·Ferring·Phase 2·NCT05403476·4 enrolled

Ovarian1 trial

A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in China

Completed·Ferring·Phase 3·NCT06173869·301 enrolled

Phase II1 trial

A Phase III Study With FE 999169 Versus Niflec for Colon Cleansing

Completed·Ferring·Phase 3·NCT02215954·637 enrolled

Bladder Cancer1 trial

Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)

Active, not recruiting·Ferring·Phase 3·NCT05704244·25 enrolled

Details

Drug Info

Related News